Categories
Archives
- 2026
- 2025
- 2024
- 2023
- 2022
- 2021
Jan
31
Voices on Value: Supporting People Impacted by Rare Disease through an Effective Policy Landscape
Jan
16
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
Dec
18
Charting the Future: UCB’s 2024 Achievements are Fueling our 2025 Ambitions
Dec
06
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
Nov
26
UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting
Nov
20
Closing gaps in HS care through community engagement and scientific innovation
Nov
20
UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa
Nov
14
New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis
Nov
14
A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology
